10-Q: American Well Corporation Reports Q1 2025 Results, Revenue Up 12% Amid Strategic Shift

American Well Corporation (Amwell) announces its Q1 2025 financial results, highlighting a 12% increase in revenue and strategic adjustments including the divestiture of Aligned Telehealth.

Summary

• American Well Corporation reported a net loss attributable to American Well Corporation of $18.7 million for the three months ended March 31, 2025, compared to a net loss of $72.1 million for the same period in 2024.
• Revenue increased by 12% to $66.8 million in Q1 2025 from $59.5 million in Q1 2024, driven by subscription revenue and professional services.
• The company divested its Aligned Telehealth business (APC) on January 8, 2025, resulting in a gain of $10.7 million.
• Total visits using Amwell's enterprise software were 1.3 million in Q1 2025, with AMG providers accounting for 29% of these visits.
• The company is focusing on its Converge platform, strategic customers, and achieving profitability.
• Operating expenses decreased by 28% due to cost-saving measures, including headcount reductions and reduced consulting spend.
• The company's adjusted EBITDA loss improved to $12.2 million in Q1 2025 from $45.7 million in Q1 2024.
• Amwell expects research and development, sales and marketing, and general and administrative expenses to decrease in the current year and then remain flat in future periods.
• The company's cash and cash equivalents totaled $222.4 million as of March 31, 2025.
• Amwell believes its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While the company still reports a net loss, there are significant improvements in revenue growth, reduced losses, and cost-saving measures. The strategic shift towards the Converge platform and focus on profitability are positive indicators, but risks remain in the competitive and regulatory landscape.

Positives

• Revenue increased by 12% year-over-year, indicating growth in the company's core business.
• Net loss significantly decreased, demonstrating improved financial performance.
• The divestiture of APC generated a gain of $10.7 million, strengthening the balance sheet.
• Adjusted EBITDA loss improved, reflecting better operational efficiency.
• Operating expenses decreased due to cost-saving measures, enhancing profitability.
• The company has a strong cash position with $222.4 million in cash and cash equivalents.
• Subscription revenue increased $7.3 million due to timing of revenue recognition related to arrangements with several strategic customers.
• Other revenue increased $4.4 million primarily related to professional services performed for our strategic customers.

Negatives

• The company still reported a net loss of $18.7 million, indicating ongoing challenges with profitability.
• Total visits decreased from 1.7 million in Q1 2024 to 1.3 million in Q1 2025.
• The sale of APC resulted in a decrease in visit revenue of $6.1 million in the three months ended March 31, 2025, which was partially offset by an increase in visit revenue of $2.1 million related to virtual primary care and special program visits.

Risks

• Weak growth and increased volatility in the digital care market could impact future performance.
• The company has a history of losses and may not achieve profitability.
• Inability to adapt to rapid technological changes could hinder competitiveness.
• Reliance on a limited number of significant clients poses a risk if their business is lost.
• Increased competition from existing and potential new participants in the healthcare industry could affect market share.
• Changes in healthcare laws, regulations, or trends could impact operations.
• Slower than expected growth in patient adoption of digital care and in platform usage could affect revenue.
• Inability to grow the base of affiliated and non-affiliated providers sufficiently to serve patient demand could limit growth.
• The continuation of the Defense Health Agency relationship beyond July of 2025 with comparable financial terms is not guaranteed.

Future Outlook

Amwell expects research and development, sales and marketing, and general and administrative expenses to decrease in the current year and then remain flat in future periods. The company believes its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.

Management Comments

• We divested the APC Business as it was determined the offering no longer fit our goals around profitability and growth.
• Streamlining our service offerings will enable us to focus our resources on the Converge platform, strategic customers, and our path to profitability.

Industry Context

The report indicates Amwell is navigating a rapidly evolving digital care market, focusing on its core platform and strategic partnerships to maintain competitiveness. The company is adapting to changes in regulatory requirements and addressing the growing demand for hybrid care solutions.

Comparison to Industry Standards

• Teladoc Health, a major competitor in the telehealth space, reported Q1 2024 revenue of $629.2 million, a 3% increase year-over-year.
• MDLive, another competitor, is privately held and does not publicly disclose its financials, making direct comparison difficult.
• Zoom, while not a direct competitor, provides video conferencing technology used in telehealth, and reported Q1 2025 revenue of $1.14 billion, a 3.2% increase year-over-year.
• Epic Systems is a major player in electronic health records and health IT, and its financial performance is not directly comparable to Amwell's telehealth services.
• Cerner, now part of Oracle, provides health information technology solutions, and its financial performance is also not directly comparable to Amwell's telehealth services.

Management Changes

Related Party Transactions

• Cleveland Clinic is a related party due to a board member being an executive advisor.
• CCAW, JV LLC is a related party as it is a joint venture between the Company and Cleveland Clinic.

Stakeholder Impact

• Shareholders: The improved financial performance and strategic focus may positively impact shareholder value.
• Employees: Headcount reductions and strategic transformation actions may affect employee morale and job security.
• Customers: The focus on the Converge platform and strategic partnerships aims to improve service delivery and customer satisfaction.
• Suppliers: Changes in business strategy and cost-saving measures may impact supplier relationships.
• Creditors: The strong cash position and improved financial performance enhance the company's creditworthiness.

Next Steps

• Continue focusing on the Converge platform and strategic customer relationships.
• Implement cost-saving measures to improve profitability.
• Monitor and adapt to changes in the regulatory environment.
• Expand the base of affiliated and non-affiliated providers to meet patient demand.

Key Dates

Keywords

telehealth, virtual care, digital health, Converge platform, subscription revenue, EBITDA, Amwell, American Well Corporation, financial results